Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Trial Profile

A Randomized, Double-blind, Multi-center Phase III Study of Brivanib versus Sorafenib as First-line Treatment in Patients with Advanced Hepatocellular Carcinoma (The BRISK FL Study)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 20 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Brivanib alaninate (Primary) ; Sorafenib
  • Indications Liver cancer
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms BRISK-FL
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 27 May 2021 Results of a retrospective analysis of data from studies Bristol Myers Squibb and AbbVie Inc (NCT00858871and NCT01009593) to quantify the rate of tumour progression in patients receiving sorafenib published in the Journal of Hepatology
    • 11 Jun 2019 A Statistical model that allows personalised survival prediction following sorafenib treatment using data from 2 trials (NCT00858871 and NCT00699374) ;results published in the British Journal of Cancer
    • 26 Aug 2013 Results published in the Journal of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top